• Explore /
  • Poster
  • / Multicenter phase 2 trial of the PARP inhibitor (PARPi) olaparib in recurrent IDH1 and IDH2-mutant contrast-enhancing glioma.

Multicenter phase 2 trial of the PARP inhibitor (PARPi) olaparib in recurrent IDH1 and IDH2-mutant contrast-enhancing glioma.

Abstract Poster

Authors

null

Kristina Fanucci

Yale Cancer Center, New Haven, CT

Kristina Fanucci , Mary Josephine Paula Pilat , Ritu Shah , Scott Anthony Boerner , Jing Li , Diane E. Durecki , Jan Drappatz , Frances A. Collichio , Vinay K. Puduvalli , Frank S. Lieberman , Javier Gonzalez , Pierre Giglio , Xun Bao , S. Percy Ivy , Ranjit Bindra , Antonio Marcilio Padula Omuro , Patricia LoRusso

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Central Nervous System Tumors

Track

Central Nervous System Tumors

Sub Track

Primary CNS Tumors–Glioma

Clinical Trial Registration Number

NCT03212274

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 2035)

DOI

10.1200/JCO.2022.40.16_suppl.2035

Abstract #

2035

Poster Bd #

373

Abstract Disclosures

Similar Posters

First Author: Lauren Schaff

First Author: Jared Cohen

First Author: Emeline Tabouret

First Author: Tae Yong Kim